EE386 Budget Impact of Durvalumab for the Treatment of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Private Healthcare System
Abstract
Authors
I. Meirelles N. Costa C. Dias M. Massaoka D.G. Lopes L. Jabase